-
Your Trusted Generics Medicine Supplier
- +91 84484 44095 / 8071 555 357
-
Mumbai, India
Eng
简体中文
العربيّة
Indications & Usage
Comprehensive information on the approved uses of Mefloquine Tablets USP 250mg for malaria treatment and prevention.
Treatment of Uncomplicated Malaria
Acute Malaria Treatment
Approved for: Treatment of mild to moderate uncomplicated malaria caused by:
Plasmodium falciparum
Most common and dangerous malaria species
Plasmodium vivax
Common in Asia and Latin America
Plasmodium malariae
Less common but widely distributed
Plasmodium ovale
Rare, found mainly in Africa
Treatment Criteria:
- Uncomplicated malaria (no severe manifestations)
- Ability to take oral medication
- No contraindications to mefloquine therapy
- Confirmed malaria diagnosis or high clinical suspicion
Malaria Prophylaxis (Prevention)
Preventive Therapy
Approved for: Prevention of malaria in travelers to endemic areas
High-Risk Geographic Areas:
Sub-Saharan Africa
High transmission areas, especially West and Central Africa
Southeast Asia
Thailand, Myanmar, Cambodia, Vietnam, Laos
South America
Amazon basin regions of Brazil, Peru, Bolivia
Indian Subcontinent
Parts of India, Pakistan, Bangladesh
Ideal Candidates for Prophylaxis:
- Short-term travelers (up to 1 year)
- Military personnel
- Aid workers and missionaries
- Business travelers to endemic areas
- Adventure travelers and tourists
Dosage Guidelines by Population
Adult Dosage
Treatment: 5 tablets (1250mg) single dose
Prophylaxis: 1 tablet (250mg) weekly
Maximum: 1250mg for treatment
Pediatric Dosage
Treatment: 25mg/kg (max 1250mg)
Prophylaxis: 5mg/kg (max 250mg)
Age: 6 months to 16 years
Special Populations
Elderly: Use with caution
Renal impairment: No adjustment needed
Hepatic impairment: Avoid if severe
Geographic Risk Assessment
High Risk Areas
- Sub-Saharan Africa (especially West Africa)
- Papua New Guinea and Solomon Islands
- Amazon basin
- Parts of Southeast Asia
Moderate Risk Areas
- South Asia (India, Bangladesh)
- Parts of Southeast Asia
- Parts of Latin America
- Caribbean islands (Haiti, Dominican Republic)
Low/No Risk Areas
- Urban areas of Southeast Asia
- Most tourist resorts
- Areas above 2000m altitude
- North Africa, Middle East
Special Population Guidance
Children
Age: 6 months to 16 years
Dosing: Weight-based calculation
Considerations: Parents must monitor for psychiatric side effects
Monitoring: Regular follow-up during prophylaxis
Pregnant Women
First Trimester: Contraindicated
Second/Third: Use only if benefits outweigh risks
Alternative: Consider other antimalarials
Consultation: Required before use
Breastfeeding Mothers
Excretion: Present in breast milk
Decision: Benefit vs risk assessment
Alternative: Consider formula feeding
Monitoring: Watch infant for side effects
Elderly Patients
Age: >65 years
Dosing: Standard adult dose
Monitoring: Increased side effect vigilance
Comorbidities: Consider cardiac/hepatic status
Resistance Information
Drug Resistance Patterns
Understanding malaria resistance is crucial for effective treatment
High Resistance Areas
- Thai-Myanmar and Thai-Cambodia borders
- Western Cambodia
- Eastern Myanmar
- Southern Vietnam
Recommendation: Alternative antimalarials preferred
Moderate Resistance Areas
- Parts of Africa (emerging resistance)
- South America (Amazon region)
- Some Pacific islands
Recommendation: Use with local resistance data
Low Resistance Areas
- Most of Sub-Saharan Africa
- Caribbean
- Central America
Recommendation: Mefloquine remains effective